Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover

Oncogene

Volumn 27, Issue 34, 2008, Pages 4678-4689

  Koch, A ^a   Scherr, M ^a   Breyer, B ^a   Mancini, A ^a   Kardinal, C ^a   Battmer, K ^a   Eder, M ^a   Tamura, T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

CD34+ cells; CML; Imatinib; Receptor internalization; TrkA and Bcr Abl

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CD34 ANTIGEN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE A; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL SURFACE; CELL SURVIVAL; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE SILENCING; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MULTIPROTEIN COMPLEXES; NERVE GROWTH FACTOR; PC12 CELLS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RATS; RECEPTOR, TRKA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

RATTUS;

EID: 49149118901     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.107     Document Type: Article

References (46)

1. Blero D, De Smedt F, Pesesse X, Paternotte N, Moreau C, Payrastre B et al. (2001). The SH2 domain containing inositol 5-phosphatase SHIP2 controls phosphatidylinositol 3,4,5-trisphosphate levels in CHO-IR cells stimulated by insulin. Biochem Biophys Res Com 282: 839-843.
2. Bonati A, Carlo-Stella C, Lunghi P, Albertini R, Pinelli S, Migliaccio E et al. (2000). Selective expression and constitutive phosphorylation of SHC proteins in the CD34+ fraction of chronic myelogenous leukemias. Cancer Res 60: 728-732.
3. Bracci-Laudiero L, Celestino D, Starace G, Antonelli A, Lambiase A, Procoli A et al. (2003). CD34-positive cells in human umbilical cord blood express nerve growth factor and its specific receptor TrkA. J Neuroimmunol 136: 130-139.
4. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. (2000). Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145.
5. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ et al. (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104.
6. Burton EA, Plattner R, Pendergast AM. (2003). Abl tyrosine kinases are required for infection by Shigella flexneri. EMBO J 22: 5471-5479.
7. Butterfield JH, Weiler D, Dewald G, Gleich GJ. (1988). Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 12: 345-355.
8. Chen Z-Y, Ieraci A, Tanowitz M, Lee FS. (2005). A novel endocytic recycling signal distinguishes biological responses of Trk neurotrophin recptors. Mol Biol Cell 16: 5761-5772.
9. Chevalier S, Praloran V, Smith C, MacGrogan D, Ip NY, Yancopoulos GD et al. (1994). Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells. Blood 83: 1479-1485.
10. Deininger M, Buchdunger E, Druker BJ. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653.
11. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. (2007). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Eng J Med 355: 2408-2417.
12. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. (2001). Activity of a specific inhibitor of the Bcr-Abltyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med 344: 1038-1042.
13. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Ablpositive cells. Nat Med 2: 561-566.
14. Feller SM. (2001). Crk family adaptors-signalling complex formation and biological roles. Oncogene 20: 6348-6371.
15. Giuriato S, Blero D, Robaye B, Bruyns C, Payrastre B, Erneux C. (2002). SHIP2 overexpression strongly reduces the proliferation rate of K562 erythroleukemia cell line. Biochem Biophys Res Commun 296: 106-110.
16. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. (2000). Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932.
17. Howe CL, Valletta JS, Rusnak AS, Mobley WC. (2001). NGF signaling from clathrin-coated vesicles: evidence that signaling endosomes serve as a platform for the Ras-MAPK pathway. Neuron 32: 801-814.
18. Huang EJ, Reichardt LF. (2003). Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72: 609-642.
19. Kaebisch A, Brokt S, Seay U, Lohmeyer J, Jaeger U, Pralle H. (1996). Expression of the nerve growth factor receptor c-TRK in human myeloid leukaemia cells. Br J Haematol 95: 102-109.
20. Koch A, Mancini A, El Bounkari O, Tamura T. (2005). The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading. Oncogene 24: 3436-3447.
21. Koch A, Mancini A, Stefan M, Niedenthal R, Niemann H, Tamura T. (2000). Direct interaction of nerve growth factor receptor, TrkA, with non-receptor tyrosine kinase, c-Abl, through the activation loop. FEBS letter 469: 72-76.
22. Mancini A, Koch A, Wilms R, Tamura T. (2002). c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms. J Biol Chem 277: 14635-14640.
23. Matsuda H, Coughlin MD, Bienenstock J, Denburg JA. (1988). Nerve growth factor promotes human hemopoietic colony growth and differentiation. Proc Natl Acad Sci USA 85: 6508-6512.
24. Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O et al. (2005). AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci USA 102: 4016-4021.
25. Muraille E, Pessese X, Kuntz C, Erneux C. (1999). Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement of SHIP-2 in negative signalling of B-cells. Biochem J 342: 697-705.
26. Obermeier A, Lammers R, Wiesmüller KH, Jung G, Schlessinger J, Ullrich A. (1993). Identification of Trk binding site for SHC and phosphatidylinositol 3′-kinase and formation of a multimeric signaling complex. J Biol Chem 268: 22963-22966.
27. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Eng J Med 348: 994-1004.
28. Rajagopal R, Chen ZY, Lee FS, Chao MV. (2004). Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. J Neurosci 24: 6650-6658.
29. Riccio A, Pierchala BA, Ciarallo CL, Ginty DD. (1997). An NGF-TrkA-mediated retrograde signal to transcription factor CREB in sympathetic neurons. Science 277: 1097-1100.
30. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. (2002). Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1: 479-492.
31. Saxena S, Howe CL, Cosgaya JM, Steiner P, Hirling H, Chan JR et al. (2005). Differential endocytic sorting of p75NTR and TrkA in response to NGF: a role for late endosomes in TrkA trafficking. Mol Cell Neurosci 28: 571-587.
32. Scheijen B, Griffin JD. (2002). Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 21: 3314-3333.
33. Scherr M, Battmer K, Blömer U, Schiedlmeier B, Ganser A, Grez M et al. (2002). Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. Blood 99: 709-712.
34. Scherr M, Battmer K, Schultheis B, Ganser A, Eder M. (2005). Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Gene Therapy 12: 12-21.
35. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M. (2003). Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101: 1566-1569.
36. Simone MD, De Santis S, Vigneti E, Papa G, Amadori S, Aloe L. (1999). Nerve growth factor: a survey of activity on immune and hematopoietic cells. Hematol Oncol 17: 1-10.
37. Snider WD. (1994). Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell 77: 627-638.
38. Stephens RM, Loeb DM, Copeland TD, Pawson T, Greene LA, Kaplan D. (1994). Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF response. Neuron 12: 691-705.
39. Tam S-Y, Tsai M, Yamaguchi M, Yano K, Butterfield JH, Galli SJ. (1997). Expression of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells. Blood 90: 1807-1820.
40. Tanos B, Pendergast AM. (2006). Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem 281: 32714-32723.
41. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD et al. (2001). STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054-5058.
42. von Bubnoff N, Peschel C, Duyster J. (2003). Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 17: 829-838.
43. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G et al. (2000). Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19: 3521-3528.
44. Wisniewski D, Strife A, Swendeman S, Erdjument-Bromage H, Geromanos S, Kavanaugh WM et al. (1999). A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 93: 2707-2720.
45. Yano H, Cong F, Birge RB, Goff SP, Chao MV. (2000). Association of the Abl tyrosine kinase with the Trk nerve growth factor receptor. J Neurosci Res 59: 356-364.
46. Zhang Y, Moheban DB, Conway BR, Bhattacharyya A, Segal RA. (2000). Cell surface Trk receptors mediate NGF-induced survival while internalized receptors regulate NGF-induced differentiation. J Neurosci 20: 5671-5678.